A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

In the late 1980s, Ambros and Ruvkun were postdoctoral researchers in the laboratory of Robert Horvitz, who received the ...

City Therapeutics launches with $135M to lead the future of RNAi-based medicine; led by founding Alnylam CEO and RNAi pioneer ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

MIT study reveals 5-fluorouracil functions by disrupting RNA, not DNA, potentially impacting cancer treatment.

In 2006, the Nobel committee awarded the medicine or physiology prize to two researchers for their discovery of a cellular mechanism called RNA interference, which microRNAs and other non-coding RNA ...

Nobel Prize for Physiology awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in ...

Victor Ambros, on the UMass faculty since 2008, and Gary Ruvkun, of Massachusetts General Hospital and Harvard Medical School ...

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Victor Ambros and Gary Ruvkun have been jointly awarded the 2024 Nobel Prize in Physiology or Medicine for the discovery of ...